Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnose...

Full description

Autores:
Isaac, Rafael H.
Gonzalez-Devia, Deyanira
Mendivil, Carlos O.
Chapman, Edgardo
Tipo de recurso:
Article of journal
Fecha de publicación:
2023
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/11154
Acceso en línea:
http://hdl.handle.net/20.500.12495/11154
https://doi.org/10.3389/falgy.2023.1201807
Palabra clave:
Reacciones adversas
Síndrome de quilomicronemia familiar
Pancreatitis
Triglicéridos
Urticaria
Volanesorsen
Adverse reactions
Familial chylomicronemia syndrome
Pancreatitis
Triglycerides
Urticaria
Volanesorsen
Rights
openAccess
License
Atribución 4.0 Internacional
id UNBOSQUE2_c17740d95c2277ed3b3a1be0b05305d4
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/11154
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
title Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
spellingShingle Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
Reacciones adversas
Síndrome de quilomicronemia familiar
Pancreatitis
Triglicéridos
Urticaria
Volanesorsen
Adverse reactions
Familial chylomicronemia syndrome
Pancreatitis
Triglycerides
Urticaria
Volanesorsen
title_short Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
title_full Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
title_fullStr Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
title_full_unstemmed Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
title_sort Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
dc.creator.fl_str_mv Isaac, Rafael H.
Gonzalez-Devia, Deyanira
Mendivil, Carlos O.
Chapman, Edgardo
dc.contributor.author.none.fl_str_mv Isaac, Rafael H.
Gonzalez-Devia, Deyanira
Mendivil, Carlos O.
Chapman, Edgardo
dc.subject.spa.fl_str_mv Reacciones adversas
Síndrome de quilomicronemia familiar
Pancreatitis
Triglicéridos
Urticaria
Volanesorsen
topic Reacciones adversas
Síndrome de quilomicronemia familiar
Pancreatitis
Triglicéridos
Urticaria
Volanesorsen
Adverse reactions
Familial chylomicronemia syndrome
Pancreatitis
Triglycerides
Urticaria
Volanesorsen
dc.subject.keywords.spa.fl_str_mv Adverse reactions
Familial chylomicronemia syndrome
Pancreatitis
Triglycerides
Urticaria
Volanesorsen
description Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnosed FCS secondary to a pathogenic variant in APOA5 and a history of recurrent hypertriglyceridemia-induced pancreatitis episodes was being treated with volanesorsen, 285 mg every 2 weeks. Treatment with volanesorsen achieved normalization of triglycerides to <200 mg/dl. However, after the fifth dose of the medication, the patient developed urticaria and volanesorsen was discontinued. In the absence of alternative pharmacological treatments, the patient received a novel desensitization protocol for volanesorsen that allowed continuation of therapy, without evidence of hypersensitivity reactions after subsequent administrations. FCS requires aggressive multimodal therapy and close follow-up. Volanesorsen has shown great efficacy, but a significant rate of discontinuation due to side effects has been observed. Here, the patient presented an immediate hypersensitivity reaction to volanesorsen, but the provision of a desensitization protocol was effective, facilitating continued treatment and impacting the survival and quality of life of the patient.
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2023-07-25T17:06:32Z
dc.date.available.none.fl_str_mv 2023-07-25T17:06:32Z
dc.date.issued.none.fl_str_mv 2023
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.local.none.fl_str_mv Artículo de revista
dc.type.hasversion.none.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.coarversion.none.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 2673-6101
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/11154
dc.identifier.doi.none.fl_str_mv https://doi.org/10.3389/falgy.2023.1201807
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 2673-6101
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/11154
https://doi.org/10.3389/falgy.2023.1201807
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Frontiers in Allergy, 2673-6101, 4, 2023, 1-5
dc.relation.uri.none.fl_str_mv https://www.frontiersin.org/articles/10.3389/falgy.2023.1201807/full
dc.rights.*.fl_str_mv Atribución 4.0 Internacional
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
Acceso abierto
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Frontiers in Allergy
dc.publisher.journal.spa.fl_str_mv Frontiers in Allergy
institution Universidad El Bosque
bitstream.url.fl_str_mv https://repositorio.unbosque.edu.co/bitstreams/45182595-6f29-40bf-9ba5-784c5d4bda5c/download
https://repositorio.unbosque.edu.co/bitstreams/c7f40a30-332b-4d03-b0d4-509598d08b21/download
https://repositorio.unbosque.edu.co/bitstreams/1e0565f6-ff83-406e-b5d0-2e00709d08aa/download
https://repositorio.unbosque.edu.co/bitstreams/b0ff0ee6-d7ad-4362-b117-f1c8f4d3acb5/download
https://repositorio.unbosque.edu.co/bitstreams/94437f7e-65d5-4831-8eda-d12c5aabe0b9/download
bitstream.checksum.fl_str_mv 79715fa43aa00e4e683ae79d5b7e85bc
0175ea4a2d4caec4bbcc37e300941108
17cc15b951e7cc6b3728a574117320f9
de938094d9b524b6402e8ab8a2374948
9ccc526b7589fbdd39eda642a9648867
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1828164474280869888
spelling Isaac, Rafael H.Gonzalez-Devia, DeyaniraMendivil, Carlos O.Chapman, Edgardo2023-07-25T17:06:32Z2023-07-25T17:06:32Z20232673-6101http://hdl.handle.net/20.500.12495/11154https://doi.org/10.3389/falgy.2023.1201807instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengFrontiers in AllergyFrontiers in AllergyFrontiers in Allergy, 2673-6101, 4, 2023, 1-5https://www.frontiersin.org/articles/10.3389/falgy.2023.1201807/fullAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessReacciones adversasSíndrome de quilomicronemia familiarPancreatitisTriglicéridosUrticariaVolanesorsenAdverse reactionsFamilial chylomicronemia syndromePancreatitisTriglyceridesUrticariaVolanesorsenCase report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsenArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnosed FCS secondary to a pathogenic variant in APOA5 and a history of recurrent hypertriglyceridemia-induced pancreatitis episodes was being treated with volanesorsen, 285 mg every 2 weeks. Treatment with volanesorsen achieved normalization of triglycerides to <200 mg/dl. However, after the fifth dose of the medication, the patient developed urticaria and volanesorsen was discontinued. In the absence of alternative pharmacological treatments, the patient received a novel desensitization protocol for volanesorsen that allowed continuation of therapy, without evidence of hypersensitivity reactions after subsequent administrations. FCS requires aggressive multimodal therapy and close follow-up. Volanesorsen has shown great efficacy, but a significant rate of discontinuation due to side effects has been observed. Here, the patient presented an immediate hypersensitivity reaction to volanesorsen, but the provision of a desensitization protocol was effective, facilitating continued treatment and impacting the survival and quality of life of the patient.ORIGINALfalgy-04-1201807.pdffalgy-04-1201807.pdfCase report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsenapplication/pdf7139389https://repositorio.unbosque.edu.co/bitstreams/45182595-6f29-40bf-9ba5-784c5d4bda5c/download79715fa43aa00e4e683ae79d5b7e85bcMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908https://repositorio.unbosque.edu.co/bitstreams/c7f40a30-332b-4d03-b0d4-509598d08b21/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82000https://repositorio.unbosque.edu.co/bitstreams/1e0565f6-ff83-406e-b5d0-2e00709d08aa/download17cc15b951e7cc6b3728a574117320f9MD53THUMBNAILfalgy-04-1201807.pdf.jpgfalgy-04-1201807.pdf.jpgIM Thumbnailimage/jpeg8306https://repositorio.unbosque.edu.co/bitstreams/b0ff0ee6-d7ad-4362-b117-f1c8f4d3acb5/downloadde938094d9b524b6402e8ab8a2374948MD54TEXTfalgy-04-1201807.pdf.txtfalgy-04-1201807.pdf.txtExtracted texttext/plain21850https://repositorio.unbosque.edu.co/bitstreams/94437f7e-65d5-4831-8eda-d12c5aabe0b9/download9ccc526b7589fbdd39eda642a9648867MD5520.500.12495/11154oai:repositorio.unbosque.edu.co:20.500.12495/111542024-02-07 02:40:58.777http://creativecommons.org/licenses/by/4.0/Atribución 4.0 Internacionalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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